AHRQ Rx Comparative Research Partners Include CMS, NIH, FDA, VA, McClellan Says
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS administrator says NIH can develop comparative evidence based on clinical trial databases and keep CMS apprised of drugs being studied. Speakers at AHRQ comparative research “town hall” point to public, private and international purchasers that could provide comparative drug information.
You may also be interested in...
Paxil Fraud Case May Spur Congressional, FDA Action – Schering Exec
Pressure is growing for greater disclosure of study results, which may shift industry R&D, Schering compliance VP Saunders says. Former DoJ attorney Bentivoglio suggests that disclosure requirements would include cost-effectiveness data.
Paxil Fraud Case May Spur Congressional, FDA Action – Schering Exec
Pressure is growing for greater disclosure of study results, which may shift industry R&D, Schering compliance VP Saunders says. Former DoJ attorney Bentivoglio suggests that disclosure requirements would include cost-effectiveness data.
AHRQ Rx Comparisons Should Focus On Existing Literature, Not Clinical Trials, McClellan Says
Clinical trials take too much time and money, CMS Administrator McClellan says. Programs mandated under Medicare Rx law, such as the chronic care improvement pilot and the Part B replacement drug demo, will provide clinical data to evaluate comparative effectiveness, he says.